Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by fouremmon Jul 09, 2013 3:42pm
76 Views
Post# 21597155

RE:RE:RE:share price

RE:RE:RE:share priceWell said BDAZ, further to your point I don't understand why the management at RVX has never spent any time proactively sharing what a few basic outcome scenario's might have meant in the real world as far as the future for RVX-208 and it's successors.  If the general shareholder base had understood that part of the reason for a primary endpoint of .6% reduction in PAV was simply because of outcome probability vs finances, and that not achieving that end point was not the end of the world, I think we all might have been spared some of this debacle.  Actually I think DM finally did a decent job on a conference call and to a degree addressed what you just said.  To bad it wasn't in the form of proactive investor education as opposed to reactive damage control.  

I would be in your latter group of longs who believes there is still significant value in RVX's IP and now it is up to management to find a way to best monetize it.
Bullboard Posts